1Bone RC, Balk RA, Cerra FB,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine [J]. Chest, 1992,101(6) 1644-1655.
4Yan ZQ, Zhou L, Zhao YK. et al. Rapid quantitative detection of Yersinia pestis by lateral-flow immunoassay and up-converting phosphor technology-based biosensor [J]. Sens Actuators B, 2006, 119(2): 656-663.
5Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine [J/OL]. BMC Infect Dis, 2006,6 65 E2006-03-30. http..//www, biomedcentral, com/1471-2334/6/65.
4Bone RC,Balk RA,Cerra FB. ACCP/SCCM definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis[J]. Chest, 1992,101:1644- 1655.
5Joan M. The role of C reactive protein in the evaluation and management of infants with suspected sepsis[J].Adv Neonatal Care,2003,3(1):3 -13.
6Povoa P, Almeida E, Moreira P,et al. C-reactive protein as an in dicator of sepsis[J]. Intensive Care Med, 2008, 24: 1052-1056.
7Claeys R,Vinken S,Spapen H,etal. Plasma procalcitonin and C- reactive protein in acute septic shock: clinical and biological corerlates[J]. Crit Care Med, 2002,30(4) :757-762.
8Haweky PM. Mechanisms of resistance to antibiotics[J]. In tensiev Caer Med, 2000,26 : 9 -13.
9Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
10Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
